Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, outlines the final results of the Phase III ASCEND study (NCT02970318), evaluating safety and efficacy of acalabrutinib monotherapy in chronic lymphocytic leukemia (CLL) patients in the relapsed/refractory (R/R) setting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).